V13L (p.Val13Leu) variant of ACTN2 (Alpha-actinin-2)

V13L (p.Val13Leu) in ACTN2 (Alpha-actinin-2) is a missense change. Clinical records from ClinVar and UniProt describe it as likely benign in the context of Cardiovascular phenotype. The available variant effect predictions contribute to a CATVariant prioritization score of 0.38 / 1. The record also includes population frequency data and structural context.

V13L (p.Val13Leu) variant details